AcelRx Pharmaceuticals Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$93.7M
Industry:Biotech
Founded:2005
Lead Investor(s):Cantor Fitzgerald & Co

Estimated Revenue & Financials

  • AcelRx Pharmaceuticals's estimated annual revenue is currently $2.2M per year.(?)
  • AcelRx Pharmaceuticals received $Undisclosed in venture funding in November 2018.
  • AcelRx Pharmaceuticals's estimated revenue per employee is $18,868
  • AcelRx Pharmaceuticals's total funding is $93.7M.

Employee Data

  • AcelRx Pharmaceuticals has 114 Employees.(?)
  • AcelRx Pharmaceuticals grew their employee count by 9% last year.
  • AcelRx Pharmaceuticals currently has 3 job openings.

AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company's product candidates, DSUVIA (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx's licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product. To learn more about the development status of these product-candidates, please visit our website at www.acelrx.com.

keywords:Biotechnology,Healthcare,Human Resources Hr,Pharmaceuticals